Botanical wellness for responsible adults Free shipping on eligible orders
Skip to Content

What the evidence actually says about cannabis

Conclusive for chronic pain. Scarce for anxiety. A reader's guide to the strongest research - with the receipts, and a chart.
3 July 2026 by
ishaan aggarwal, ishaan aggarwal

Ask the internet whether cannabis "works" and you'll get two loud answers: miracle and menace. The research says something quieter and more useful. Here is what the strongest reviews actually found — with the receipts.

The short answer

Evidence strength depends entirely on what you ask about. For chronic pain, it is genuinely strong. For chemotherapy-related nausea and MS-related muscle stiffness, respectable. For sleep, modest. For anxiety, depression and most mental-health uses — despite what half of Instagram will tell you — it is thin. Anyone who flattens that picture, in either direction, is selling something.

Strength of evidence, by use 0 = insufficient • 3 = conclusive/substantial — NASEM 2017; Black et al. 2019 Chronic pain (adults) conclusive Chemo-related nausea substantial MS muscle spasticity moderate Sleep quality limited–moderate Anxiety & mental health limited (“scarce”) Darker = stronger evidence. Ratings are for cannabis-based medicines generally, not any specific product.
Chart: Kushiva, from National Academies (2017) and Black et al., The Lancet Psychiatry (2019).

Where the evidence is strong

The most comprehensive review ever conducted — the U.S. National Academies of Sciences' 2017 report, which weighed over 10,000 studies — put it plainly:

"There is conclusive or substantial evidence that cannabis or cannabinoids are effective for the treatment of chronic pain in adults."
NASEM, The Health Effects of Cannabis and Cannabinoids, 2017

The same report found substantial evidence for chemotherapy-induced nausea and vomiting, and moderate evidence for multiple-sclerosis spasticity. Note the word choices — effective is not the same as dramatic. Benefits in trials are typically modest, and responses vary a great deal between individuals. Our pain evidence page goes deeper.

Where it is honest to say "we don't know yet"

In 2019, researchers pooled 83 studies covering nearly 3,500 people for The Lancet Psychiatry — the largest look at cannabinoids and mental health to date. Their conclusion:

"There is scarce evidence to suggest that cannabinoids improve depressive disorders and symptoms, anxiety disorders, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder, or psychosis."
Black et al., The Lancet Psychiatry, 2019

"Scarce" is not "zero" — research continues, and some people report short-term calm. But nobody honest can promise mental-health results today. We keep our own stress and mood pages updated with exactly this framing.

What about safety?

The World Health Organization's expert committee reviewed cannabidiol in 2018 and found that "CBD is generally well tolerated with a good safety profile," adding that reported adverse effects were often the result of interactions with patients' existing medications — which is precisely why a doctor should know everything you take. The risks that are real — drowsiness, dependency in some users, psychiatric effects in susceptible people, driving impairment — are catalogued honestly in our safety guide.

How to read cannabis research yourself

Three habits will make you sharper than most of the internet:

  • Prefer reviews over single studies. One exciting trial means little; NASEM-style syntheses of hundreds mean a lot.
  • Watch the language. "Conclusive," "moderate," "limited," "insufficient" — these words are chosen carefully. Marketing removes them; science keeps them.
  • Check who benefits. A brand quoting only the favourable half of a review is answering a different question than you are asking.

That, in one paragraph, is our whole philosophy: Questions Before Conclusions. Start at the Education Center if you want the full tour — or the plain-language FAQ if you just want your questions answered.

Sources

Educational content, not medical advice. Individual responses vary; consult a qualified doctor. For responsible adults (18+).

Vijaya: the 4,000-year story of cannabis in India
From the Atharvaveda's 'joy-giver' to the NDPS Act's leaf carve-out and today's AYUSH-licensed medicines - how India kept an ancient plant, and added paperwork.
Explore Kushiva Shop the full range
Shop now